- Home
- ACB vs OBIO Comparison
ACB vs OBIO Comparison
Compare ACB & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACB | OBIO |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 188.3M | 246.2M |
| IPO Year | 2016 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ACB | OBIO |
|---|---|---|
| Price | $3.68 | $4.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $14.25 |
| AVG Volume (30 Days) | ★ 587.5K | 160.1K |
| Earning Date | 02-04-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $33,482,000.00 |
| Revenue This Year | $6.31 | N/A |
| Revenue Next Year | N/A | $12.43 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1169.22 |
| 52 Week Low | $3.07 | $2.20 |
| 52 Week High | $6.67 | $5.42 |
Technical Indicators
Market Signals| Indicator | ACB | OBIO |
|---|---|---|
| Relative Strength Index (RSI) | 61.00 | 57.18 |
| Support Level | $3.28 | $4.02 |
| Resistance Level | $3.91 | $4.76 |
| Average True Range (ATR) | 0.14 | 0.23 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 97.71 | 87.39 |
Price Performance
Historical ComparisonAbout ACB Aurora Cannabis Inc.
Aurora Cannabis Inc headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. Although the company operates in Canada, it has expanded internationally through medical cannabis exporting agreements. The company opertes in Canada, Europe, Australia, and Others, with majority revenue from Canada.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.